Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
Open Access
- 14 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 32 (3), 595-606
- https://doi.org/10.1007/s00198-020-05802-5
Abstract
Summary The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. Introduction To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy. Methods A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered soluble ALN compared with generic ALN, denosumab, zoledronic acid and no treatment. Pooled efficacy data derived from the NICE network meta-analysis were used for bisphosphonate treatments. Two treatment duration scenarios were assessed: 1 year using persistence data derived from an Italian prospective observational study including 144 and 216 postmenopausal osteoporotic women on buffered soluble ALN and oral ALN, respectively, and 3 years. Analyses were conducted for women 60–80 years of age with a bone mineral density T-score ≤ − 3.0 or with existing vertebral fractures. Results In all simulated populations, buffered soluble ALN was dominant (more QALYs, lower costs) compared to denosumab. The cost per QALY gained of buffered soluble ALN compared to generic ALN and no treatment always falls below €20,000 per QALY gained. In the 1-year treatment scenario, zoledronic acid was associated with more QALY than buffered soluble ALN but the cost per QALY gained of zoledronic acid compared with buffered soluble ALN was always higher than €70,000, while buffered soluble ALN was dominant in the 3-year treatment scenario. Conclusion This study suggests that buffered soluble ALN represents a cost-effective strategy compared with relevant alternative treatments for postmenopausal osteoporosis women in Italy aged 60 years and over.Keywords
Funding Information
- EffRx Pharmaceuticals
This publication has 49 references indexed in Scilit:
- Modulation of gastric pH by a buffered soluble effervescent formulation: A possible means of improving gastric tolerability of alendronateInternational Journal of Pharmaceutics, 2012
- A new taxonomy for describing and defining adherence to medicationsBritish Journal of Clinical Pharmacology, 2012
- Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in BelgiumPharmacoEconomics, 2011
- A reappraisal of generic bisphosphonates in osteoporosisOsteoporosis International, 2011
- Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tabletOsteoporosis International, 2011
- The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patientsHealth Policy, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2009
- Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in OsteoporosisValue in Health, 2009
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisThe New England Journal of Medicine, 2007
- A meta-analysis of previous fracture and subsequent fracture riskBone, 2004